



Influenza Reagent
Influenza Virus Infectious BVR-26 (B/Austria/1359417/2021)
(B/Victoria)
NIBSC code: 25/264
Instructions for use
(Version 1.0, Dated 06/11/2025)

§

1. INTENDED USE

Reagent 25/264 is prepared from BVR-26 (B-Victoria lineage), a reassortant of B/Austria/1359417/2021 and B/Brisbane/46/2015, which was processed in 250 µL volumes as liquid stock. The known passage history of BVR-26 is attached.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material.

4. CONTENTS

Country of origin of biological material: United Kingdom.
Each ampoule contains 250 µL (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hens' eggs.

5. STORAGE

Store in the dark at -70°C or below.
Material type: Liquid – will be shipped according to the storage and shipping conditions of the product

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution

8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

N/A.

10. ACKNOWLEDGEMENTS

N/A.

11. FURTHER INFORMATION

Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
<http://www.who.int/biologicals/en/>
JCTLM Higher order reference materials:
<http://www.bipm.org/en/committees/jc/jctlm/>
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
<http://www.nibsc.org/products/ordering.aspx>
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Clear liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify): Live influenza virus	
Toxicological properties	
Effects of inhalation:	Likelihood of influenza infection, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.



Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or

upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

Net weight: 0.25g per vial

Toxicity Statement: Non-toxic

Veterinary certificate or other statement if applicable.

Attached: No

Passage History of BVR-26 (B/Austria/1359417/2021) (B/Victoria)

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E3	E3	VW10042525	VIDRL, Australia
E12	E3/E9	533B	Seqirus, Australia
E13	E3/E9/E1	46670*	MHRA, UK

*The HA titre of this virus using 0.7% turkey red blood cells is 128. The infectious titre is unknown.

Sterility: no visible contamination was detected in a variety of media (tryptone soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequences of this virus are available upon request.



REPORT

Derivation of BVR-26 B/Austria/1359417/2021 – High Growth Reassortant

B/Austria/1359417/2021 (BVR-26) is a B high growth reassortant influenza virus.

PREPARATION

The preparation of B/Austria/1359417/2021 (BVR-26) high growth reassortant influenza virus was conducted in R&D Influenza Operations Department at Seqirus.

The high yielding parent strain used was B/Brisbane/46/2015.

MATERIALS

The following materials of biological origin were used during the preparation of high growth reassortant BVR-26:

Virus Isolate:

The virus isolate was obtained from the WHO Collaborating Centre for Reference & Research on Influenza, Melbourne.

Supply details are:

B/Austria/1359417/2021

Laboratory number: VW10042525

Passages prior to receipt at Seqirus: 3

Eggs:

Specific Pathogen Free (SPF) eggs were used for all passages at Seqirus.

Antiserum:

Monoclonal Antibody BBR3.7E8.1B9 (15/03/19B) raised against influenza virus B/Brisbane/60/2008.

The MAb was prepared from murine hybridoma cells derived from mice immunized with inactivated B/Brisbane/60/2008 influenza virus.

Note on Transmissible Spongiform Encephalopathies (TSEs):

Australia and New Zealand have been declared TSE free in accordance with OIE guidelines. Detailed information on Australia's animal health status can be obtained from the following Animal Health Australia website link: <https://animalhealthaustralia.com.au>

The MAb was gamma irradiated at 35kGrays prior to use.



REPORT

PASSAGE HISTORY:

<i>Mixed infection passage:</i> (E3/D1)	B/Austria/1359417/2021 wild type virus @10 ⁻³ x B/Brisbane/46/2015 @10 ⁻⁵ ↓	HA titre = ND
<i>1st Antiserum Passage</i> (E3/D2)	Inoculum @ 10 ⁻³ with Mab to B/Brisbane/60/2008 ↓	HA titre = 10
<i>2nd Antiserum Passage</i> (E3/D3)	Inoculum @ 10 ⁻³ with Mab to B/Brisbane/60/2008 ↓	HA titre = 520
<i>3rd Antiserum/ 1st Limit Dilution Passage**</i> (E3/D4)	Inoculum @ 10 ⁻⁹ ↓	HA titre = 57
<i>4th Antiserum/ 2nd Limit Dilution Passage**</i> (E3/D5)	Inoculum @ 10 ⁻⁷ ↓	HA titre = 453
<i>5th Limit Dilution Passage</i> (E3/D6)	Inoculum @ 10 ⁻⁴ ↓	HA titre = 970
<i>6th Limit Dilution Passage</i> (E3/D7)	Inoculum @ 10 ⁻⁹ ↓	HA titre = 251
<i>7th Limit Dilution Passage</i> (E3/D8)	Inoculum @ 10 ⁻⁸ ↓	HA titre = 299
<i>8th Limit Dilution Passage</i> Lot 533B (E3/D9) BVR-26	Inoculum @ 10 ⁻⁴	Mean HA titre = 1029



REPORT

Total number of passages post mixed infection = 8

Total number of passages since this virus was received from an approved laboratory = 9

HA titres were determined using fowl red blood cells at room temperature.

** Virus sample diluted to 10⁻³ dilution was mixed with Mab to B/Brisbane/60/2008 and incubated for 1 hour at room temperature. Incubated virus/MAb sample was serially diluted and inoculated into eggs at indicated dilution.

TESTING OF B/AUSTRIA/1359417/2021 (BVR-26) INFLUENZA VIRUS

Test	Result		
Genotype (by DNA sequencing)	6:2 (B/Brisbane/46/2015: B/Austria/1359417/2021) Reassortant B/Austria/1359417/2021 (wild type virus) HA and NA were detected. B/Brisbane/46/2015 (HGP) PB1, PB2, PA, NP, Matrix and NS genes were detected.		
	Gene	B/Austria/1359417/2021	B/Brisbane/46/2015
	HA	√	X
	NA	√	X
	PB1	X	√
	PB2	X	√
	PA	X	√
	NP	X	√
	M	X	√
	NS	X	√

√ - positive by Sequencing

X - negative by Sequencing

Disclaimer:

The material i.e. high growth reassortant virus BVR-26 and the information provided in this derivation report are provided on an “as is” basis and as such without any warranty or representation of any kind (expressed or implied) including, without limitation, of satisfactory quality or fitness for a particular purpose.



Medicines & Healthcare products
Regulatory Agency



NIBSC
Confidence in Biological Medicines